Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Terce LaboratoriesBOM:524314 +1.01%58 EBITDA Margin % is 3.20% as of Mar. 2026, which is 27% above its 10-year median of 2.52. GuruFocus rates BOM:524314 with a GF Score™ of 58/100 and a GF Value™ of ₹44.92 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Gujarat Terce Laboratories ranks worse than 61.73% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gujarat Terce Laboratories EBITDA Margin % Related Terms
Gujarat Terce Laboratories EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524314 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Terce Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gujarat Terce Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Terce Laboratories (BOM:524314) has a EBITDA Margin % of 3.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gujarat Terce Laboratories and its competitors. This is 27% above median its historical median of 2.52. According to the industry distribution chart, Gujarat Terce Laboratories ranks #592 out of 959 companies in the Drug Manufacturers industry, placing it in the top 61.7%.
Is Gujarat Terce Laboratories' EBITDA Margin % too high?
Gujarat Terce Laboratories' current EBITDA Margin % of 3.20% is 27% above median its 10-year median of 2.52. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Gujarat Terce Laboratories' value of 3.20% is 74.4% below this industry median. Based on the distribution chart, Gujarat Terce Laboratories ranks #592 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gujarat Terce Laboratories has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Terce Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gujarat Terce Laboratories ranks #592 out of 959 companies for EBITDA Margin %. This places Gujarat Terce Laboratories in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Gujarat Terce Laboratories' value of 3.20% is 74.4% below this benchmark. While the company's 10-year median is 2.52 vs. the industry median of 12.49, Gujarat Terce Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Terce Laboratories's current EBITDA Margin % of 3.20% is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gujarat Terce Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Terce Laboratories's current EBITDA Margin % is 3.20%, which is 27% above median its own 10-year median of 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Terce Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Terce Laboratories (BOM:524314) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹44.92, compared to a current price of ₹35.00 — trading 22.1% below its estimated fair value. The current EBITDA Margin % is 3.20%, which is 27% above median its 10-year median of 2.52 and 74.4% below the Drug Manufacturers industry median of 12.49. Gujarat Terce Laboratories' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gujarat Terce Laboratories (BOM:524314), the current EBITDA Margin % is 3.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Terce Laboratories (BOM:524314) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Terce Laboratories stock appears to be undervalued.
The current stock price of ₹35.00 is trading 22.1% below its estimated GF Value™ of ₹44.92.
GuruFocus considers Gujarat Terce Laboratories to be Modestly Undervalued.
Key valuation signals for BOM:524314:
EBITDA Margin %: 3.20% (27% above median its 10-year median of 2.52)
GF Value™: ₹44.92 vs. price of ₹35.00 (22.1% below fair value)
Industry Position: 74.4% below the Drug Manufacturers median (#592 of 959)
No single metric tells the full story. See the BOM:524314 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Terce Laboratories Ltd is an Indian company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, syrup, and injections. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, antifungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash, Aziter, and others.
58GF Score
Get the complete analysis for BOM:524314
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524314 has been successfully added to your 
